Book contents
- Frontmatter
- Contents
- List of contributors
- Foreword: The future of drug discovery and healthcare
- Acknowledgments
- 1 The art and science of the drug discovery pipeline
- 2 Computational approaches to drug target identification
- 3 Understanding human disease knowledge through text mining
- 4 Integrating translational biomarkers into drug development
- 5 Computational phenotypic assessment of small molecules in drug discovery
- 6 Data visualization and the DDP process
- 7 Information visualization – important IT considerations
- 8 Example of computational biology at the new drug application (NDA) and regulatory approval stages
- 9 Clinical trial failures and drug repositioning
- Appendix I Additional knowledge-based analysis approaches
- Appendix II Open source tools and public data sources
- Index
- Plate section
- References
9 - Clinical trial failures and drug repositioning
Published online by Cambridge University Press: 05 February 2016
Edited by
Book contents
- Frontmatter
- Contents
- List of contributors
- Foreword: The future of drug discovery and healthcare
- Acknowledgments
- 1 The art and science of the drug discovery pipeline
- 2 Computational approaches to drug target identification
- 3 Understanding human disease knowledge through text mining
- 4 Integrating translational biomarkers into drug development
- 5 Computational phenotypic assessment of small molecules in drug discovery
- 6 Data visualization and the DDP process
- 7 Information visualization – important IT considerations
- 8 Example of computational biology at the new drug application (NDA) and regulatory approval stages
- 9 Clinical trial failures and drug repositioning
- Appendix I Additional knowledge-based analysis approaches
- Appendix II Open source tools and public data sources
- Index
- Plate section
- References
Summary
More than 90% of compounds entering clinical trials fail to reach the market; thus, any company with a history in drug development has a large number of failed compounds “sitting on the shelf.” Each of these compounds has a substantial portfolio of associated data and represents a significant sunk cost. This chapter discusses methods to find new uses for failed clinical-stage compounds (repositioning), and highlights a specific current example to discuss the unique development considerations for a repositioned compound.
Background
There is a long and rich history of successful drug repositioning. This includes repositioning of compounds during their first clinical development program, repositioning of compounds that failed in their original development program, and repositioning (or line extension) of marketed drugs. Selected examples are shown in Table 9.1. While the development strategies for new uses of marketed and failed compounds differ in regulatory, intellectual property and market protection considerations, the strategies for exploring for new uses are similar.
There has recently been a concerted effort in many pharmaceutical companies to systematically review all failed clinical candidates (FCC). This is driven by several considerations. First, there is general recognition that the highly focused approach necessary in the original development may have precluded consideration of all possible uses. Second, modern compound testing and data analysis paradigms are readily optimized for repositioning. Third, when a new development path is found, the development cost for an FCC could be significantly lower than the cost of de novo development of a new compound, as a large amount of proprietary non-clinical and clinical data exist for the FCC.
Information
- Type
- Chapter
- Information
- Publisher: Cambridge University PressPrint publication year: 2016
References
1. Sosei announces progression of SD118 towards phase 1 studies. February 21, 2007. www.sosei.com/en/news/pdf/PR_20070221-e.pdf
2. Ore Pharmaceuticals focuses resources on development of repositioned compounds. June 16, 2008. www.orepharma.com/ir-press-releases
3. Dynogen presents results of its positive phase 2a IBS-c Study with DDP733 (Pumosetrag). 22 May 2008. www.medicalnewstoday.com/articles/108338.php and Dynogen acquires exclusive rights to pumosetrag. Dec 1, 2004 http://findarticles.com/p/articles/mi_m0DHC/is_12_16/ai_n6358241/
4. Ore Pharmaceuticals acquires repositioned clinical-stage drug candidate from Roche. July 31, 2008. www.orepharma.com/ir-press-releases
5. Melior Discovery announces IND approval for novel diabetes drug MLR1023. March 16, 2009. www.meliordiscovery.com/pdfs/IND%20approval%203-09pdf.pdf
6. and . Drug repositioning: Identifying and developing new uses for existing drugs. Nature Reviews Drug Discovery. 2004;3:673–683.CrossRefGoogle ScholarPubMed
7. , , and Use of broad biological profiling as a relevant descriptor to describe and differentiate compounds: Structure-in vitro (pharmacology-ADME)-in vivo (safety) relationships. In Antitargets: Prediction and Prevention of Drug Side Effects, ed. and (pp. 23–52). Weinheim:Wiley-VCH Verlag, 2008.Google Scholar
8. , , and . Biological mechanism profiling using an annotated compound library. Chemistry & Biology. 2003;10:881–892.CrossRefGoogle ScholarPubMed
9. and . Emerging applications of kinetic biomarkers in preclinical and clinical drug development. Current Opinion in Drug Discovery & Development. 2005;8:115–126.Google ScholarPubMed
10. , , and Prediction of biological targets for compounds using multiple-category Bayesian models trained on chemogenomics databases. Journal of Chemical Information Modeling. 2006;46:1124–1133.CrossRefGoogle ScholarPubMed
11. and Neighborhood behavior of in silico structural spaces with respect to in vitro activity spaces – A novel understanding of the molecular similarity principle in the context of multiple receptor binding profiles. Journal of Chemical Information and Computing Sciences. 2003;43:680–690.Google ScholarPubMed
12. , , and Biological spectra analysis: Linking biological activity profiles to molecular structure. Proceedings of the National Academy of Sciences, USA. 2005;102:261–266.CrossRefGoogle ScholarPubMed
13. , , and Biological spectra analysis: Model Proteome characterizations for linking molecular structure and biological response. Journal of Medicinal Chemistry. 2005;48:6918–6925.CrossRefGoogle ScholarPubMed
14. , , and Analysis of drug induced effect patterns to link structure and side effects of medicines. Nature Chemistry and Biology. 2005;1:389–397.CrossRefGoogle ScholarPubMed
15. , and How many drug targets are there?Nature Reviews Drug Discovery. 2006;5:993–996.CrossRefGoogle Scholar
16. From genes to whole organs: Connecting biochemistry to physiology. Novartis Foundation Symposia. 2001;239:111–123.Google ScholarPubMed
17. , , , et al. Discovery of novel hippocampal neurogenic agents by using an in vivo stable isotope labeling technique. Journal of Pharmacology and Experimental Therapeutics. 2006;319:1172–1181.Google Scholar
18. , , , et al. Measurement of brain microglial proliferation rates in vivo in response to neuroinflammatory stimuli: application to drug discovery. Journal of Neuroscience Research. 2007;85:2374–2384.CrossRefGoogle ScholarPubMed
20. United States Patent 3,922,345 Lipinski, et al. November 25, 1975.
21. , , , and The lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of Type-2 diabetes. Journal of Pharmacology and Experimental Therapy. 2013;342:23–32.Google Scholar
22. , , , and MLR-1023 is a potent and selective allosteric activator of lyn kinase in vitro that improves glucose tolerance in vivo. Journal of Pharmacology and Experimental Therapy. 2013;342:15–22.Google Scholar
Accessibility standard: Unknown
Accessibility compliance for the PDF of this book is currently unknown
and may be updated in the future.